The HARMONY Alliance is using Big Data to develop more personalized treatments for blood cancer patients. This is a team effort involving hospitals, academic institutions, pharmaceutical companies, regulatory agencies, and patient organizations. In our 2021 BigDataForBloodCancer awareness campaign, we engaged with a broad audience to explain what Big Data can mean for the lives of patients and for the daily work of doctors in the clinic. In addition, we launched the 1st World Big Data for Blood Cancer day on 30 September 2021.
Scan, read or watch our selected content below and find out how innovative big data analytic tools can speed up research for the good of the patients.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
